

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	N-Terminal acetyltransferase complex ARD1 subunit homolog A (NAA10; ARD1A; ARD1); DNA (cytosine-5-)-methyltransferase 1 (DNMT1)	<i>In vitro</i> , mouse and patient sample studies suggest that inhibiting NAA10 could help treat cancer. In human lung cancer samples, high levels of NAA10 correlated with poor prognosis. In cultures or mouse xenografts of NAA10-overexpressing lung cancer cells, small interfering RNA knockdown of NAA10 led to less cellular proliferation and tumor growth than those seen using scrambled siRNA control. Next steps include identifying compounds that prevent NAA10 from interacting with DNMT1, a methyltransferase that regulates the activity of NAA10. SuperGen Inc.'s SGI-110, a DNMT1 inhibitor, is in preclinical testing to treat cancer.	Findings unpatented; unavailable for licensing	Lee, C.-F. <i>et al. J. Clin. Invest.</i> ; published online July 1, 2010; doi:10.1172/JCI42275 Contact: Cheng-Wen Wu, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan e-mail: ken@ibms.sinica.edu.tw Contact: Li-Jung Juan, Genomics Research Center, Academia Sinica, Taipei, Taiwan e-mail: ljjuan@gate.sinica.edu.tw
		SciBX 3(28); doi:10.1038/scibx.2010.856 Published online July 22, 2010		